WO2002022585A1 - Composes de tetrahydroquinoline - Google Patents
Composes de tetrahydroquinoline Download PDFInfo
- Publication number
- WO2002022585A1 WO2002022585A1 PCT/JP2001/007991 JP0107991W WO0222585A1 WO 2002022585 A1 WO2002022585 A1 WO 2002022585A1 JP 0107991 W JP0107991 W JP 0107991W WO 0222585 A1 WO0222585 A1 WO 0222585A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- group
- carbon atoms
- substituted
- alkyl
- alkyl group
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
- C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
- C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D215/20—Oxygen atoms
- C07D215/22—Oxygen atoms attached in position 2 or 4
- C07D215/233—Oxygen atoms attached in position 2 or 4 only one oxygen atom which is attached in position 4
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/08—Drugs for disorders of the urinary system of the prostate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/14—Drugs for dermatological disorders for baldness or alopecia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
- A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
- A61P5/26—Androgens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
- A61P5/28—Antiandrogens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/06—Antianaemics
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
- C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
- C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D215/36—Sulfur atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
- C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
- C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D215/38—Nitrogen atoms
- C07D215/42—Nitrogen atoms attached in position 4
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
- C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
- C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D215/38—Nitrogen atoms
- C07D215/42—Nitrogen atoms attached in position 4
- C07D215/44—Nitrogen atoms attached in position 4 with aryl radicals attached to said nitrogen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
- C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
- C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D215/48—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F7/00—Compounds containing elements of Groups 4 or 14 of the Periodic System
- C07F7/02—Silicon compounds
- C07F7/08—Compounds having one or more C—Si linkages
- C07F7/18—Compounds having one or more C—Si linkages as well as one or more C—O—Si linkages
- C07F7/1804—Compounds having Si-O-C linkages
Description
Claims
Priority Applications (5)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP01965645A EP1325914A4 (en) | 2000-09-14 | 2001-09-14 | TETRAHYDROQUINOLINE COMPOUNDS |
CA002422137A CA2422137A1 (en) | 2000-09-14 | 2001-09-14 | Tetrahydroquinoline compounds |
JP2002526838A JPWO2002022585A1 (ja) | 2000-09-14 | 2001-09-14 | テトラヒドロキノリン化合物 |
US10/380,589 US6777427B2 (en) | 2000-09-14 | 2001-09-14 | Tetrahydroquinoline compounds |
AU2001286243A AU2001286243A1 (en) | 2000-09-14 | 2001-09-14 | Tetrahydroquinoline compounds |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2000-279180 | 2000-09-14 | ||
JP2000279180 | 2000-09-14 |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2002022585A1 true WO2002022585A1 (fr) | 2002-03-21 |
Family
ID=18764228
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/JP2001/007991 WO2002022585A1 (fr) | 2000-09-14 | 2001-09-14 | Composes de tetrahydroquinoline |
Country Status (6)
Country | Link |
---|---|
US (1) | US6777427B2 (ja) |
EP (1) | EP1325914A4 (ja) |
JP (1) | JPWO2002022585A1 (ja) |
AU (1) | AU2001286243A1 (ja) |
CA (1) | CA2422137A1 (ja) |
WO (1) | WO2002022585A1 (ja) |
Cited By (25)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2005018573A2 (en) | 2003-08-22 | 2005-03-03 | Ligand Pharmaceuticals Incorporated | 6-cycloamino-2-quinolinone derivatives as androgen receptor modulator compounds |
US7211672B2 (en) | 2002-10-04 | 2007-05-01 | Millennium Pharmaceuticals, Inc. | PGD2 receptor antagonists for the treatment of inflammatory diseases |
US7504508B2 (en) | 2002-10-04 | 2009-03-17 | Millennium Pharmaceuticals, Inc. | PGD2 receptor antagonists for the treatment of inflammatory diseases |
US7622503B2 (en) | 2000-08-24 | 2009-11-24 | University Of Tennessee Research Foundation | Selective androgen receptor modulators and methods of use thereof |
JP2010513558A (ja) * | 2006-12-18 | 2010-04-30 | ノバルティス アーゲー | 4−イミダゾリル−1,2,3,4−テトラヒドロキノリン誘導体、およびアルドステロン/11−ベータ−ヒドロキシラーゼ阻害剤としてのその使用 |
US7772433B2 (en) | 2002-02-28 | 2010-08-10 | University Of Tennessee Research Foundation | SARMS and method of use thereof |
US7951950B2 (en) | 2005-02-24 | 2011-05-31 | Millennium Pharmaceuticals, Inc. | PGD2 receptor antagonists for the treatment of inflammatory diseases |
US8193357B2 (en) | 2005-06-17 | 2012-06-05 | Ligand Pharmaceuticals Incorporated | Androgen receptor modulator compounds |
US8309603B2 (en) | 2004-06-07 | 2012-11-13 | University Of Tennessee Research Foundation | SARMs and method of use thereof |
JP2013529597A (ja) * | 2010-06-11 | 2013-07-22 | サノフイ | 集中的還元的アミノ化によるフェロキンの合成方法 |
US8519158B2 (en) | 2004-03-12 | 2013-08-27 | Ligand Pharmaceuticals Incorporated | Androgen receptor modulator compounds and methods |
US8853266B2 (en) | 2001-12-06 | 2014-10-07 | University Of Tennessee Research Foundation | Selective androgen receptor modulators for treating diabetes |
US9150501B2 (en) | 2007-09-11 | 2015-10-06 | Gtx, Inc. | Solid forms of selective androgen receptor modulators |
JP2016519665A (ja) * | 2013-03-15 | 2016-07-07 | ヒューマン バイオモレキュラー リサーチ インスティチュートHuman BioMolecular Resarch Institute | 骨の成長および修復に使用するための化合物およびマトリックス |
US9604916B2 (en) | 2012-07-13 | 2017-03-28 | Gtx, Inc. | Method of treating androgen receptor (AR)-positive breast cancers with selective androgen receptor modulator (SARMs) |
US9622992B2 (en) | 2012-07-13 | 2017-04-18 | Gtx, Inc. | Method of treating androgen receptor (AR)-positive breast cancers with selective androgen receptor modulator (SARMs) |
US9730908B2 (en) | 2006-08-24 | 2017-08-15 | University Of Tennessee Research Foundation | SARMs and method of use thereof |
US9744149B2 (en) | 2012-07-13 | 2017-08-29 | Gtx, Inc. | Method of treating androgen receptor (AR)-positive breast cancers with selective androgen receptor modulator (SARMs) |
US9844528B2 (en) | 2006-08-24 | 2017-12-19 | University Of Tennessee Research Foundation | SARMs and method of use thereof |
US9884038B2 (en) | 2004-06-07 | 2018-02-06 | University Of Tennessee Research Foundation | Selective androgen receptor modulator and methods of use thereof |
US9889110B2 (en) | 2004-06-07 | 2018-02-13 | University Of Tennessee Research Foundation | Selective androgen receptor modulator for treating hormone-related conditions |
US9969683B2 (en) | 2012-07-13 | 2018-05-15 | Gtx, Inc. | Method of treating estrogen receptor (ER)-positive breast cancers with selective androgen receptor modulator (SARMS) |
US10258596B2 (en) | 2012-07-13 | 2019-04-16 | Gtx, Inc. | Method of treating HER2-positive breast cancers with selective androgen receptor modulators (SARMS) |
US10314807B2 (en) | 2012-07-13 | 2019-06-11 | Gtx, Inc. | Method of treating HER2-positive breast cancers with selective androgen receptor modulators (SARMS) |
US10849873B2 (en) | 2012-07-13 | 2020-12-01 | Oncternal Therapeutics, Inc | Non-invasive method of evaluating breast cancers for selective androgen receptor modulator (SARM) therapy |
Families Citing this family (17)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US7919647B2 (en) | 2000-08-24 | 2011-04-05 | University Of Tennessee Research Foundation | Selective androgen receptor modulators and methods of use thereof |
US7645898B2 (en) * | 2000-08-24 | 2010-01-12 | University Of Tennessee Research Foundation | Selective androgen receptor modulators and method of use thereof |
US20070173546A1 (en) * | 2000-08-24 | 2007-07-26 | Dalton James T | Selective androgen receptor modulators and method of use thereof |
US7855229B2 (en) * | 2000-08-24 | 2010-12-21 | University Of Tennessee Research Foundation | Treating wasting disorders with selective androgen receptor modulators |
US20070161608A1 (en) * | 2001-12-06 | 2007-07-12 | Dalton James T | Selective androgen receptor modulators for treating muscle wasting |
EA013738B1 (ru) * | 2003-10-14 | 2010-06-30 | Юниверсити Оф Теннесси Рисерч Фаундейшн | Лечение нарушений костной ткани с использованием селективных модуляторов адрогенных рецепторов |
EP2305352A1 (en) | 2004-04-02 | 2011-04-06 | Merck Sharp & Dohme Corp. | 5-alpha-reductase inhibitors for use in the treatment of men with metabolic and anthropometric disorders |
US20110237664A1 (en) * | 2004-06-07 | 2011-09-29 | Dalton James T | Selective androgen receptor modulators for treating diabetes |
BRPI0513119A (pt) * | 2004-07-14 | 2008-04-29 | Ligand Pharm Inc | compostos e métodos modulares de receptores intracelulares |
US10010521B2 (en) | 2006-08-24 | 2018-07-03 | University Of Tennessee Research Foundation | SARMs and method of use thereof |
WO2009103007A2 (en) * | 2008-02-13 | 2009-08-20 | Ligand Pharmaceuticals Incorporated | Steroid hormone receptor modulator compounds and methods |
EP2276345A4 (en) | 2008-04-24 | 2012-06-06 | Univ California | SMALL MOLECULAR INHIBITORS OF THE ANDROGEN RECEPTOR |
CN103002737A (zh) * | 2010-01-11 | 2013-03-27 | Gtx公司 | 治疗睑板腺功能障碍的方法 |
SG11202111402PA (en) | 2019-05-14 | 2021-11-29 | Nuvation Bio Inc | Anti-cancer nuclear hormone receptor-targeting compounds |
US11952349B2 (en) | 2019-11-13 | 2024-04-09 | Nuvation Bio Inc. | Anti-cancer nuclear hormone receptor-targeting compounds |
BR112023019420A2 (pt) | 2021-03-23 | 2023-10-24 | Nuvation Bio Inc | Compostos de direcionamento ao receptor de hormônio nuclear anticâncer |
JP2024516024A (ja) | 2021-05-03 | 2024-04-11 | ニューベイション・バイオ・インコーポレイテッド | 抗がん核内ホルモン受容体標的化化合物 |
Citations (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GB2069498A (en) * | 1980-02-19 | 1981-08-26 | Riker Laboratories Inc | Substituted- tetrahydroquinaldines, intermediates for 6,7-dihydro-9- fluoro-5-methyl-1-oxo-1H,5H- benzo(ij)quinolizine-2-carboxylic Acid |
EP0385271A1 (en) * | 1989-02-27 | 1990-09-05 | Eastman Kodak Company | Tetrahydroquinolines and method of preparation |
WO1996019458A2 (en) * | 1994-12-22 | 1996-06-27 | Ligand Pharmaceuticals Incorporated | Steroid receptor modulator compounds and methods |
EP0987251A1 (en) * | 1998-09-17 | 2000-03-22 | Pfizer Products Inc. | 4-carboxyamino-2-methyl-1,2,3,4-tetrahydroquinolines as CETP inhibitors |
WO2000017164A1 (en) * | 1998-09-17 | 2000-03-30 | Pfizer Products Inc. | 4-carboxyamino-2-substituted-1,2,3,4-tetrahydroquinolines as cetp inhibitors |
Family Cites Families (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5693646A (en) * | 1994-12-22 | 1997-12-02 | Ligand Pharmaceuticals Incorporated | Steroid receptor modulator compounds and methods |
-
2001
- 2001-09-14 WO PCT/JP2001/007991 patent/WO2002022585A1/ja active Application Filing
- 2001-09-14 EP EP01965645A patent/EP1325914A4/en not_active Withdrawn
- 2001-09-14 AU AU2001286243A patent/AU2001286243A1/en not_active Abandoned
- 2001-09-14 US US10/380,589 patent/US6777427B2/en not_active Expired - Fee Related
- 2001-09-14 JP JP2002526838A patent/JPWO2002022585A1/ja active Pending
- 2001-09-14 CA CA002422137A patent/CA2422137A1/en not_active Abandoned
Patent Citations (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GB2069498A (en) * | 1980-02-19 | 1981-08-26 | Riker Laboratories Inc | Substituted- tetrahydroquinaldines, intermediates for 6,7-dihydro-9- fluoro-5-methyl-1-oxo-1H,5H- benzo(ij)quinolizine-2-carboxylic Acid |
EP0385271A1 (en) * | 1989-02-27 | 1990-09-05 | Eastman Kodak Company | Tetrahydroquinolines and method of preparation |
WO1996019458A2 (en) * | 1994-12-22 | 1996-06-27 | Ligand Pharmaceuticals Incorporated | Steroid receptor modulator compounds and methods |
EP0987251A1 (en) * | 1998-09-17 | 2000-03-22 | Pfizer Products Inc. | 4-carboxyamino-2-methyl-1,2,3,4-tetrahydroquinolines as CETP inhibitors |
WO2000017164A1 (en) * | 1998-09-17 | 2000-03-30 | Pfizer Products Inc. | 4-carboxyamino-2-substituted-1,2,3,4-tetrahydroquinolines as cetp inhibitors |
Non-Patent Citations (13)
Title |
---|
CHEMICAL ABSTRACTS, vol. 59, 1963, Columbus, Ohio, US; abstract no. 9973B, XP002903085 * |
CLERICI,ANGELO ET AL.: "Arylative amination of aldehydes promoted by aqueous titanium trichloride", TETRAHEDRON LETTERS, vol. 31, no. 14, 1990, pages 2069 - 2072, XP002954147 * |
CRABB,TREVOR A. ET AL.: "Microbiological transformations. Part 12. The stereochemistry of some derivatives of 2,6-dimethyl-1,2,3,4-tetrahydroquinolin-4-ol. Single crystal x-ray analyses of cis- and trans-1-benzoyl-4-benzoyloxy-2,6-dimethyl-1,2,3,4-tetrahydroquinoline", J. CHEMICAL SOCIETY, PERKIN TRANS. 1, no. 1, 1994, pages 9 - 13, XP002954145 * |
DAUPHINEE G.A. ET AL.: "1,2-Dihydroquinolines: preparation and isolation as intermediates in the synthesis of quinolines", CAN. J. CHEMICAL, vol. 56, no. 5, 1978, pages 632 - 634, XP002951779 * |
FORREST,T.P. ET AL.: "Mechanism and stereochemistry of the hydrolysis of 4-arylamino-1,2,3,4-tetrahydroquinaldines", CAN. J. CHEMICAL, vol. 52, no. 6, 1974, pages 884 - 887, XP008040383 * |
FORREST,T.P. ET AL.: "On the mechaism of disproportionation reactions of 1,2-dihydroquinolines", CAN. J. CHEMICAL, vol. 63, no. 2, 1985, pages 412 - 417, XP002954148 * |
KATRITZKY,ALAN R. ET AL.: "Reactions of N-alkyl-N-phenyl-1H-benzotriazole-1-methanamines with N-vinylamides and N-vinylcarbazole. A convenient synthesis of 4-(dialkylamino) tetrahydroquinolines", J. ORGANIC CHEM., vol. 60, no. 13, 1995, pages 3993 - 4001, XP002954144 * |
KATRITZKY,ALAN R. ET AL.: "Synthesis of pyrido(4,3,2-de)quinazolines via nitro-substituted tetrahydroquinolines", J. HETEROCYCL. CHEM., vol. 36, no. 3, 1999, pages 755 - 759, XP002954142 * |
NARASAKI,KOICHI ET AL.: "Boron trifluoride etherate-catalyzed (4+2)-cycloaddition reactions of N-aryl schiff bases with 1-alkenyl, 1,2-propadienyl and 1-alkynyl sulfides", HETEROCYCLES, vol. 35, no. 2, 1993, pages 1039 - 1053, XP002954146 * |
PARK,KOON HA ET AL.: "One step synthesis of 4-ethoxy-1,2,3,4-tetrahydroquinoline from nitroarene and ethanol: a TiO2 mediated photocatalytic reaction", TETRAHEDRON LETTERS, vol. 36, no. 33, 1995, pages 5943 - 5946, XP002954143 * |
See also references of EP1325914A4 * |
ZALUKAEV,L.P. ET AL.: "Bolman bands in tetrahydroquinolines", ZH. OBSHCH. KHIM., vol. 44, no. 10, 1974, pages 2305 - 2306, XP002903087 * |
ZALUKAEV,L.P. ET AL.: "Structure of 2-methyl-4-(N-acetanilino)-6-bromo-1,2,3,4-tetrahydroquinoline", ZH. STRUKT. KHIM., vol. 16, no. 2, 1975, pages 237 - 241 * |
Cited By (37)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US7622503B2 (en) | 2000-08-24 | 2009-11-24 | University Of Tennessee Research Foundation | Selective androgen receptor modulators and methods of use thereof |
US8853266B2 (en) | 2001-12-06 | 2014-10-07 | University Of Tennessee Research Foundation | Selective androgen receptor modulators for treating diabetes |
US7772433B2 (en) | 2002-02-28 | 2010-08-10 | University Of Tennessee Research Foundation | SARMS and method of use thereof |
US7211672B2 (en) | 2002-10-04 | 2007-05-01 | Millennium Pharmaceuticals, Inc. | PGD2 receptor antagonists for the treatment of inflammatory diseases |
US7504508B2 (en) | 2002-10-04 | 2009-03-17 | Millennium Pharmaceuticals, Inc. | PGD2 receptor antagonists for the treatment of inflammatory diseases |
US7816372B2 (en) | 2003-08-22 | 2010-10-19 | Ligand Pharmaceuticals Incorporated | 6-cycloamino-2-quinolinone derivatives as androgen receptor modulator compounds |
WO2005018573A2 (en) | 2003-08-22 | 2005-03-03 | Ligand Pharmaceuticals Incorporated | 6-cycloamino-2-quinolinone derivatives as androgen receptor modulator compounds |
US8519158B2 (en) | 2004-03-12 | 2013-08-27 | Ligand Pharmaceuticals Incorporated | Androgen receptor modulator compounds and methods |
US9359285B2 (en) | 2004-03-12 | 2016-06-07 | Ligand Pharmaceuticals Incorporated | Androgen receptor modulator compounds and methods |
US8865918B2 (en) | 2004-03-12 | 2014-10-21 | Ligand Pharmaceuticals Incorporated | Androgen receptor modulator compounds and methods |
US8309603B2 (en) | 2004-06-07 | 2012-11-13 | University Of Tennessee Research Foundation | SARMs and method of use thereof |
US10053418B2 (en) | 2004-06-07 | 2018-08-21 | University Of Tennessee Research Foundation | Selective androgen receptor modulator and methods of use thereof |
US10662148B2 (en) | 2004-06-07 | 2020-05-26 | University Of Tennessee Research Foundation | Selective androgen receptor modulator and methods of use thereof |
US8669286B2 (en) | 2004-06-07 | 2014-03-11 | University Of Tennessee Research Foundation | SARMs and method of use thereof |
US9889110B2 (en) | 2004-06-07 | 2018-02-13 | University Of Tennessee Research Foundation | Selective androgen receptor modulator for treating hormone-related conditions |
US9884038B2 (en) | 2004-06-07 | 2018-02-06 | University Of Tennessee Research Foundation | Selective androgen receptor modulator and methods of use thereof |
US9278914B2 (en) | 2004-06-07 | 2016-03-08 | University Of Tennessee Research Foundation | SARMs and method of use thereof |
US7951950B2 (en) | 2005-02-24 | 2011-05-31 | Millennium Pharmaceuticals, Inc. | PGD2 receptor antagonists for the treatment of inflammatory diseases |
US8580811B2 (en) | 2005-06-17 | 2013-11-12 | Ligand Pharmaceuticals Incorporated | Androgen receptor modulator methods |
US8193357B2 (en) | 2005-06-17 | 2012-06-05 | Ligand Pharmaceuticals Incorporated | Androgen receptor modulator compounds |
US9730908B2 (en) | 2006-08-24 | 2017-08-15 | University Of Tennessee Research Foundation | SARMs and method of use thereof |
US10300037B2 (en) | 2006-08-24 | 2019-05-28 | University Of Tennessee Research Foundation | SARMs and method of use thereof |
US9844528B2 (en) | 2006-08-24 | 2017-12-19 | University Of Tennessee Research Foundation | SARMs and method of use thereof |
JP2010513558A (ja) * | 2006-12-18 | 2010-04-30 | ノバルティス アーゲー | 4−イミダゾリル−1,2,3,4−テトラヒドロキノリン誘導体、およびアルドステロン/11−ベータ−ヒドロキシラーゼ阻害剤としてのその使用 |
US11090283B2 (en) | 2007-09-11 | 2021-08-17 | University Of Tennessee Research Foundation | Solid forms of selective androgen receptor modulators |
US9150501B2 (en) | 2007-09-11 | 2015-10-06 | Gtx, Inc. | Solid forms of selective androgen receptor modulators |
JP2013529597A (ja) * | 2010-06-11 | 2013-07-22 | サノフイ | 集中的還元的アミノ化によるフェロキンの合成方法 |
JP2016145214A (ja) * | 2010-06-11 | 2016-08-12 | サノフイ | 集中的還元的アミノ化によるフェロキンの合成方法 |
US9622992B2 (en) | 2012-07-13 | 2017-04-18 | Gtx, Inc. | Method of treating androgen receptor (AR)-positive breast cancers with selective androgen receptor modulator (SARMs) |
US9969683B2 (en) | 2012-07-13 | 2018-05-15 | Gtx, Inc. | Method of treating estrogen receptor (ER)-positive breast cancers with selective androgen receptor modulator (SARMS) |
US10258596B2 (en) | 2012-07-13 | 2019-04-16 | Gtx, Inc. | Method of treating HER2-positive breast cancers with selective androgen receptor modulators (SARMS) |
US9744149B2 (en) | 2012-07-13 | 2017-08-29 | Gtx, Inc. | Method of treating androgen receptor (AR)-positive breast cancers with selective androgen receptor modulator (SARMs) |
US10314807B2 (en) | 2012-07-13 | 2019-06-11 | Gtx, Inc. | Method of treating HER2-positive breast cancers with selective androgen receptor modulators (SARMS) |
US9604916B2 (en) | 2012-07-13 | 2017-03-28 | Gtx, Inc. | Method of treating androgen receptor (AR)-positive breast cancers with selective androgen receptor modulator (SARMs) |
US10849873B2 (en) | 2012-07-13 | 2020-12-01 | Oncternal Therapeutics, Inc | Non-invasive method of evaluating breast cancers for selective androgen receptor modulator (SARM) therapy |
US10987334B2 (en) | 2012-07-13 | 2021-04-27 | University Of Tennessee Research Foundation | Method of treating ER mutant expressing breast cancers with selective androgen receptor modulators (SARMs) |
JP2016519665A (ja) * | 2013-03-15 | 2016-07-07 | ヒューマン バイオモレキュラー リサーチ インスティチュートHuman BioMolecular Resarch Institute | 骨の成長および修復に使用するための化合物およびマトリックス |
Also Published As
Publication number | Publication date |
---|---|
JPWO2002022585A1 (ja) | 2004-01-22 |
CA2422137A1 (en) | 2003-03-13 |
US20030216428A1 (en) | 2003-11-20 |
US6777427B2 (en) | 2004-08-17 |
AU2001286243A1 (en) | 2002-03-26 |
EP1325914A1 (en) | 2003-07-09 |
EP1325914A4 (en) | 2004-11-17 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
WO2002022585A1 (fr) | Composes de tetrahydroquinoline | |
KR100731566B1 (ko) | 테트라히드로퀴놀린 유도체 | |
US5618833A (en) | 1-benzyl-1,3-dihydroindol-2-one derivatives, their preparation and the pharmaceutical compositions in which they are present | |
JP2693233B2 (ja) | アミノアルカリインドール、その製法及びエストロゲン依存性疾患及び腫瘍の治療剤 | |
US5663431A (en) | 1-benzenesulfonyl-1,3-dihydro-indol-2-one derivatives, their preparation and pharmaceutical compositions in which they are present | |
US5726322A (en) | 1-benzenesulfonyl-1,3-dihydroindol-2-one derivatives, their preparation and pharmaceutical compositions in which they are present | |
NZ264122A (en) | Substituted 1-benzenesulphonyl dihydroindolones; medicaments | |
HUT68642A (en) | N-sulphonyl-2-oxoindole derivatives having affinity for vasopressin and/or ocytocin receptors | |
WO2008128100A1 (en) | Small-molecule inhibitors of the androgen receptor | |
EP4066841A1 (en) | Androgen receptor down-regulating agents and uses thereof | |
WO2011098035A1 (zh) | 一种青藤碱衍生物、合成方法及其用途 | |
JPWO2008001859A1 (ja) | オピオイドδ受容体アゴニスト | |
JP5137578B2 (ja) | プロゲステロン受容体モジュレーターとしての三置換チオフェン | |
WO2004000816A1 (ja) | アンドロゲン受容体アゴニスト | |
WO2004013104A1 (ja) | 新規テトラヒドロキノリン誘導体 | |
KR102446212B1 (ko) | 2환식 피리딘 화합물 | |
US7910584B2 (en) | 3-spiroindolin-2-one derivatives, preparation and therapeutic use thereof | |
JP2003073374A (ja) | 2環性芳香族アミン誘導体 | |
US20070191367A1 (en) | 3-spiroindolin-2-one derivatives, preparation and therapeutic use thereof | |
CN107973780B (zh) | 一种取代的烯烃类化合物及其制备方法和用途 | |
TW201118073A (en) | Hexahydrocyclopentyl [F] indazole pyridyl ethanols and derivatives thereof as selective glucocorticoid receptor modulators | |
US20160052936A1 (en) | Spiroindoline derivatives for use as gonadotropin-releasing hormone receptor antagonists | |
TW201542564A (zh) | 螺二氫吲哚衍生物及其醫藥組合物 | |
UA73499C2 (en) | Thioxyndol derivatives, pharmaceutical composition containing said derivatives and active ingredients of medicaments for the stimulation of contraception and treatment of disfunctional bleeding with carcin and adenocarcin |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AK | Designated states |
Kind code of ref document: A1 Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ PH PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZW |
|
AL | Designated countries for regional patents |
Kind code of ref document: A1 Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG |
|
DFPE | Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101) | ||
121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
WWE | Wipo information: entry into national phase |
Ref document number: 2001965645 Country of ref document: EP Ref document number: 2002526838 Country of ref document: JP |
|
WWE | Wipo information: entry into national phase |
Ref document number: 10380589 Country of ref document: US Ref document number: 2422137 Country of ref document: CA |
|
WWP | Wipo information: published in national office |
Ref document number: 2001965645 Country of ref document: EP |
|
REG | Reference to national code |
Ref country code: DE Ref legal event code: 8642 |